Prohibited medications prior to Visit 1, by time interval. Table S2. Summary of ECG abnormalities meeting the withdrawal criteria. Table S3. Summary of Holter abnormalities meeting the withdrawal criteria. Public

File Details

Depositor: rkati
Date Uploaded: 2019-05-06
Date Modified: 2019-05-06
Fixity Check: Fixity checks have not yet been run on this object
Characterization: File Format: msword (Microsoft Word Binary File Format)

Page Count: 3

File Size: 89088

Original Checksum: 53831c8fd17a36c921511b5e77568c91

Mime Type: application/msword

User Activity	Date
User rkati@ad.unc.edu has attached Prohibited medications prior to Visit 1, by time interval. Table S2. Summary of ECG abnormalities meeting the withdrawal criteria. Table S3. Summary of Holter abnormalities meeting the withdrawal criteria. to Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study	May 6th, 2019 20:54